Considering Patient Fitness and Genetics in AML Treatment Planning

Four leading experts in hematology and oncology explore the key patient characteristics that guide the selection of optimal treatments for acute myeloid leukemia (AML). Moderated by Amer M. Zeidan, MBBS, of Yale School of Medicine, the panel discusses the critical roles of patient fitness, genetic mutations, and other biomarkers in tailoring treatment approaches. Gain a deeper understanding of how these factors influence decision-making in AML care and the strategies used to achieve the best possible outcomes for each patient.